NHR2 inhibitors
- 總結
- Treatment of AML by inhibitors of NHR2 and/or RUNX1/ETO-tetramerization provides a therapy option with a unique mode of action.
- 技術優勢
- Compounds for treatment of AML
Unique mode of action
Medical use/compound protection achievable
In vivo data from mouse model available
Access to inventor know-how
- 技術應用
- Treatment of acute myeloid leukemia
- 詳細技術說明
- The formation and onset of the prevalent form of acute myeloid leukemia (AML, FAB subtype M2) requires RUNX1/ETO, the product of the t(8;21) chromosomal translocation. Tetramerization through the nervy homology region 2 (NHR2) of ETO is essential for the RUNX1/ETO-mediated transformation. The inventors demonstrated that inhibition of NHR2 tetramerization by first-in-class small molecules is a viable entry point for the treatment of AML.
- 合作類型
- Licensing
- 申請日期
- 25/04/2014 00:00:00
- 申請號碼
- WO2014EP58449 20140425
- 分類
- - international:
C07C59/70
- cooperative:
C07C59/68; C07C59/70; C07D207/337; C07D209/42; C07D235/28; C07D239/22; C07D307/68; C07D317/60; C07D471/04; C07D493/04; G01N27/447; G01N33/5011; G01N2333/47
- 其他
- Patent application
- ID號碼
- 3409
- 國家/地區
- 德國
欲了解更多信息，請點擊 這裡
